Latest & greatest articles for memantine

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on memantine or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on memantine and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for memantine

1. Memantine for prophylaxis of episodic migraine: a systematic review and meta-analysis Full Text available with Trip Pro

Memantine for prophylaxis of episodic migraine: a systematic review and meta-analysis Memantine for prophylaxis of episodic migraine: a systematic review and meta-analysis | Research Square Browse Tools & Services Your Cart This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its (...) validity or suitability for dissemination as established information or for guiding clinical practice. Research article Memantine for prophylaxis of episodic migraine: a systematic review and meta-analysis Mark Willy Llapitan Mondia, Adrian Espiritu, Martha Lu Bolaños, Artemio, Jr. A. Roxas Mark Willy Llapitan Mondia Philippine General Hospital Corresponding Author ORCiD: https://orcid.org/0000-0001-8862-5360 Adrian Espiritu Philippine General Hospital Martha Lu Bolaños Philippine General Hospital

2020 Research Square

2. The role of NMDA receptor antagonists, amantadine and memantine, in schizophrenia treatment: a systematic review Full Text available with Trip Pro

The role of NMDA receptor antagonists, amantadine and memantine, in schizophrenia treatment: a systematic review The role of NMDA receptor antagonists, amantadine and memantine, in schizophrenia treatment: a systematic review Services on Demand Journal Article Indicators Cited by SciELO Related links Similars in SciELO Share Print version ISSN 0101-6083 On-line version ISSN 1806-938X Arch. Clin. Psychiatry (São Paulo) vol.46 no.6 São Paulo Nov./Dec. 2019 Epub Nov 28, 2019 http://dx.doi.org (...) /10.1590/0101-60830000000218 Review article The role of NMDA receptor antagonists, amantadine and memantine, in schizophrenia treatment: a systematic review BRUNO TERRA JUNHO VICTOR FERNANDES DE OLIVEIRA 1 Department of Mental Health , Faculty of Medical Sciences of Minas Gerais , Belo Horizonte , MG , Brazil . 2 Department of Clinical and Toxicological Analyses , School of Pharmaceutical Sciences , University of São Paulo , São Paulo , SP , Brazil . Objective Schizophrenia is a complex and chronic

2019 Archives of Clinical Psychiatry (São Paulo)

3. Deprescribing cholinesterase inhibitors and memantine in dementia: guideline summary Full Text available with Trip Pro

Deprescribing cholinesterase inhibitors and memantine in dementia: guideline summary Deprescribing cholinesterase inhibitors and memantine in dementia: guideline summary | The Medical Journal of Australia mja-search search Use the for more specific terms. Title contains Body contains Date range from Date range to Article type Author's surname Volume First page doi: 10.5694/mja__.______ Search Reset  close Individual Login Purchase options Connect person_outline Login keyboard_arrow_down (...) Individual Login Purchase options menu search Advertisement close Deprescribing cholinesterase inhibitors and memantine in dementia: guideline summary Emily Reeve, Barbara Farrell, Wade Thompson, Nathan Herrmann, Ingrid Sketris, Parker J Magin, Lynn Chenoweth, Mary Gorman, Lyntara Quirke, Graeme Bethune and Sarah N Hilmer Med J Aust 2019; 210 (4): . || doi: 10.5694/mja2.50015 Published online: 4 March 2019 Topics Abstract Introduction: Cholinesterase inhibitors (ChEIs) and memantine are medications used

2019 MJA Clinical Guidelines

4. Comparative efficacy between ketamine, memantine, riluzole and d-cycloserine in patients diagnosed with drug resistant depression: a meta-analysis Full Text available with Trip Pro

Comparative efficacy between ketamine, memantine, riluzole and d-cycloserine in patients diagnosed with drug resistant depression: a meta-analysis Comparative efficacy between ketamine, memantine, riluzole and d-cycloserine in patients diagnosed with drug resistant depression: a meta-analysis | Darji | International Journal of Basic & Clinical Pharmacology User Username Password Remember me Journal Content Search Search Scope Browse Font Size Information Notifications Article Tools Email (...) this article (Login required) > > DOI: Comparative efficacy between ketamine, memantine, riluzole and d-cycloserine in patients diagnosed with drug resistant depression: a meta-analysis Nishita H. Darji, Devang A. Rana, Supriya D. Malhotra Abstract Background: Glutamate modulators are having immense potential and are newer entities for treating drug resistant depression. The objectives were to generate statistical evidence on basis of existing data of ketamine, memantine, riluzole and d-cycloserine

2019 International Journal of Basic & Clinical Pharmacology

5. A systematic review of economic evaluations of the use of memantine alone or combined with donepezil for moderate to severe Alzheimer’s disease Full Text available with Trip Pro

A systematic review of economic evaluations of the use of memantine alone or combined with donepezil for moderate to severe Alzheimer’s disease A systematic review of economic evaluations of the use of memantine alone or combined with donepezil for moderate to severe Alzheimer’s disease Services on Demand Journal Article text in Indicators Cited by SciELO Related links Similars in SciELO Share Print version ISSN 1809-9823 On-line version ISSN 1981-2256 Rev. bras. geriatr. gerontol. vol.22 no.4 (...) Rio de Janeiro 2019 Epub Nov 25, 2019 http://dx.doi.org/10.1590/1981-22562019022.190002 Review Articles A systematic review of economic evaluations of the use of memantine alone or combined with donepezil for moderate to severe Alzheimer’s disease Ione Ayala Gualandi de Oliveira Rosângela Caetano Ricardo Ewback Steffen Aline Navega Biz 1 Universidade do Estado do Rio de Janeiro (UERJ), Instituto de Medicina Social. Rio de Janeiro, RJ, Brasil. Objective: To synthesize the available evidence

2019 Revista Brasileira de Geriatria e Gerontologia

6. Augmentation of Antipsychotic Treatment with Memantine in Patients with Schizophrenia: A Systematic Review and Meta-Analysis Full Text available with Trip Pro

Augmentation of Antipsychotic Treatment with Memantine in Patients with Schizophrenia: A Systematic Review and Meta-Analysis T�rk Psikiyatri Dergisi - Online Yay�nc�l�k Sistemi Accepted for publication T�rk�e Ba�l�k / Turkish Title: �izofreni Hastalar�nda Antipsikotik Tedavinin Memantin ile G��lendirilmesi: Bir Sistematik G�zden Ge�irme ve Metaanaliz �ngilizce Ba�l�k / English Title: Augmentation of Antipsychotic Treatment with Memantine in Patients with Schizophrenia: A Systematic Review

2019 Turkish Journal of Psychiatry

7. Memantine

Memantine Top results for memantine - Trip Database or use your Google+ account Find evidence fast ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4 (...) ) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for memantine The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted

2018 Trip Latest and Greatest

8. Evidence-based Clinical Practice Guideline for Deprescribing Cholinesterase Inhibitors and Memantine

Evidence-based Clinical Practice Guideline for Deprescribing Cholinesterase Inhibitors and Memantine Evidence-based Clinical Practice Guideline for Deprescribing Cholinesterase Inhibitors and Memantine Developing organisations: The University of Sydney NHMRC Partnership Centre: Dealing with Cognitive and Related Functional Decline in Older People (Cognitive Decline Partnership Centre) Bruyère Research Institute, Deprescribing Guidelines in the Elderly Project Evidence-based clinical practice (...) guideline for deprescribing cholinesterase inhibitors and memantine: 2018 2 © The University of Sydney ISBN Online: 978-0-6482658-0-1 ISBN Print: 978-0-6482658-1-8 Publication date: February 2018 Suggested citation: Reeve E, Farrell B, Thompson W, Herrmann N, Sketris I, Magin P, Chenoweth L, Gorman M, Quirke L, Bethune G, Forbes F, Hilmer S. Evidence-based Clinical Practice Guideline for Deprescribing Cholinesterase Inhibitors and Memantine. Sydney: The University of Sydney; 2018. The full guideline

2018 Clinical Practice Guidelines Portal

9. Multiple sclerosis: Memantine

Multiple sclerosis: Memantine Memantine | Prescribing information | Multiple sclerosis | CKS | NICE Search CKS… Menu Memantine Multiple sclerosis: Memantine Last revised in October 2019 Memantine The use of memantine for oscillopsia in people with multiple sclerosis is off-label. For prescribing information, see the section on in the CKS topic on . © .

2018 NICE Clinical Knowledge Summaries

10. Combined treatment with memantine and galantamine-CR compared with galantamine-CR only in antidementia drug naïve patients with mild-to-moderate Alzheimer's disease. Full Text available with Trip Pro

Combined treatment with memantine and galantamine-CR compared with galantamine-CR only in antidementia drug naïve patients with mild-to-moderate Alzheimer's disease. Several studies have tested the N-methyl-D-aspartate-receptor antagonist memantine as an add-on to pre-existing treatment with acetylcholinesterase inhibitors. The objective of this study was to evaluate the efficacy and safety of a combined memantine and galantamine-CR de novo regimen compared with galantamine-CR only treatment (...) in never treated patients with mild-to-moderate Alzheimer's disease (AD).Antidementia drug-naïve participants (n = 232) with probable, mild-to-moderate AD, and mini-mental state examination scores between 15 and 26 (inclusive) were randomized to receive either 20 mg/day memantine plus 24 mg/day galantamine-CR or 24 mg/day galantamine-CR plus placebo in a 52-week, prospective, double-blind, controlled trial. The primary outcome measurement was the change on the Alzheimer's disease assessment scale

2015 Alzheimer's & dementia (New York, N. Y.) Controlled trial quality: predicted high

11. Efficacy of memantine in the treatment of fibromyalgia: A double-blind, randomised, controlled trial with 6-month follow-up (Abstract)

Efficacy of memantine in the treatment of fibromyalgia: A double-blind, randomised, controlled trial with 6-month follow-up Fibromyalgia (FM) is a prevalent and disabling chronic disease. Recent studies have found elevated levels of glutamate in several brain regions, leading to hypotheses about the usefulness of glutamate-blocking drugs such as memantine in the treatment of FM. The aim of this study was to evaluate the efficacy of memantine in the treatment of pain and other clinical variables (...) (global function, clinical impression, depression, anxiety, quality of life) in FM patients. A double-blind, parallel randomised controlled trial was developed. A total of 63 patients diagnosed with FM were recruited from primary health care centres in Zaragoza, Spain. Memantine was administered at doses of 20mg/d after 1 month of titration. Assessments were carried out at baseline, posttreatment, and 3- and 6-month follow-up. Compared with a placebo group, memantine significantly decreased ratings

2014 EvidenceUpdates Controlled trial quality: predicted high

12. Namzaric (memantine hydrochloride extended-release/donepezil hydrochloride) Capsules

Namzaric (memantine hydrochloride extended-release/donepezil hydrochloride) Capsules Namzaric (memantine hydrochloride extended-release/donepezil hydrochloride) Capsules U.S. Department of Health and Human Services Search FDA Submit search Namzaric (memantine hydrochloride extended-release/donepezil hydrochloride) Capsules Namzaric (memantine hydrochloride extended-release/donepezil hydrochloride) Capsules Company: Forest Laboratories, Inc. Application No.: 206439 Approval Date: 12/23/2014

2014 FDA - Drug Approval Package

13. Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM-AD VA cooperative randomized trial. Full Text available with Trip Pro

Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM-AD VA cooperative randomized trial. Although vitamin E and memantine have been shown to have beneficial effects in moderately severe Alzheimer disease (AD), evidence is limited in mild to moderate AD.To determine if vitamin E (alpha tocopherol), memantine, or both slow progression of mild to moderate AD in patients taking an acetylcholinesterase inhibitor.Double-blind, placebo-controlled, parallel-group (...) , randomized clinical trial involving 613 patients with mild to moderate AD initiated in August 2007 and concluded in September 2012 at 14 Veterans Affairs medical centers.Participants received either 2000 IU/d of alpha tocopherol (n = 152), 20 mg/d of memantine (n = 155), the combination (n = 154), or placebo (n = 152).Alzheimer's Disease Cooperative Study/Activities of Daily Living (ADCS-ADL) Inventory score (range, 0-78). Secondary outcomes included cognitive, neuropsychiatric, functional, and caregiver

2014 JAMA Controlled trial quality: predicted high

14. Nemdatine - memantine

Nemdatine - memantine London, 21 February 2013 EMA/228869/2013 Committee for Medicinal Products for Human Use (CHMP) Assessment report Nemdatine International non-proprietary name: Memantine Procedure No. EMEA/H/C/002680 Assessment Report as adopted by the CHMP with all information of a commercially confidential nature deleted 7 Westferry Circus ? Canary Wharf ? London E14 4HB ? United Kingdom An agency of the European Union Telephone +44 (0)20 7418 8400 Facsimile +44 (0)20 7418 8545 E-mail (...) a Marketing Authorisation to Nemdatine. Assessment report EMA/CHMP/87358/2013 Page 6/19 2. Scientific discussion 2.1. Introduction Nemdatine 5 mg, 10 mg, 15 mg and 20 mg film coated tablets is a generic medicinal product of Ebixa, which has been authorised in the EU since 15 May 2002. The active substance of Nemdatine is memantine hydrochloride, a psychoanaleptic, anti-dementia drug (N06DX01). Memantine is a voltage-dependent, moderate-affinity non-competitive N-methyl-D- aspartate (NMDA) receptor

2013 European Medicines Agency - EPARs

15. Memantine Mylan

Memantine Mylan London, 21 February 2013 EMA/229868/2013 Committee for Medicinal Products for Human Use (CHMP) Assessment report Memantine Mylan International non-proprietary name: Memantine Procedure No. EMEA/H/C/002660 Assessment Report as adopted by the CHMP with all commercially confidential information removed 7 Westferry Circus ? Canary Wharf ? London E14 4HB ? United Kingdom An agency of the European Union Telephone +44 (0)20 7418 8400 Facsimile +44 (0)20 7418 8545 E-mail info (...) . Conclusions on the chemical, pharmaceutical and biological aspects 11 2.3. Non-clinical aspects 11 2.3.1. Introduction 11 2.3.2. Ecotoxicity/environmental risk assessment 12 2.3.3. Discussion on non-clinical aspects 12 2.3.4. Conclusion on the non-clinical aspects 12 2.4. Clinical aspects 12 2.5. Pharmacovigilance 19 3. Benefit-risk balance 20 4. Recommendation 20 Memantine Mylan EMA/CHMP/91208/2013 Page 2/21 List of abbreviations AAS Atomic Absorption Spectrometry AP Applicant’s Part API Active

2013 European Medicines Agency - EPARs

16. Marixino (previously Maruxa) - memantine

Marixino (previously Maruxa) - memantine 7 Westferry Circus ? Canary Wharf ? London E14 4HB ? United Kingdom An agency of the European Union Telephone +44 (0)20 7418 8400 Facsimile +44 (0)20 7418 8416 E-mail info@ema.europa.eu Website www.ema.europa.eu © European Medicines Agency, 2013. Reproduction is authorised provided the source is acknowledged. 17 January 2013 EMA/293975/2013 Committee for Medicinal Products for Human Use (CHMP) Assessment report Maruxa International non-proprietary name (...) : Memantine Procedure No. EMEA/H/C/002658 Assessment report as adopted by the CHMP with all commercially confidential information deleted Assessment report EMA/293975/2013 Page 2/20 Product information Marketing authorisation application Name of the medicinal product: Maruxa Applicant: Krka d.d. Novo mesto Šmarješka cesta 6 8501 Novo mesto SLOVENIA Active substance: Memantine hydrochloride International Nonproprietary Name: Memantine Pharmaco-therapeutic group (ATC Code): Other anti-dementia drugs(N06DX01

2013 European Medicines Agency - EPARs

17. Memantine ratiopharm

Memantine ratiopharm 7 Westferry Circus ? Canary Wharf ? London E14 4HB ? United Kingdom An agency of the European Union Telephone +44 (0)20 7418 8400 Facsimile +44 (0)20 7418 8613 E-mail info@ema.europa.eu Website www.ema.europa.eu © European Medicines Agency, 2013. Reproduction is authorised provided the source is acknowledged. 21 March 2013 EMA/328117/2013 Committee for Medicinal Products for Human Use (CHMP) Memantine ratiopharm memantine Procedure No. EMEA/H/C/002671/0000 Assessment report (...) for initial marketing authorisation application Assessment report as adopted by the CHMP with all commercially confidential information deleted Memantine Ratiopharm CHMP assessment report Page 1/19 Table of contents 1. Background information on the procedure 3 1.1. Submission of the dossier 3 1.2. Steps taken for the assessment of the product 4 2. Scientific discussion 5 2.1. Introduction 5 2.2. Quality aspects 5 2.2.1. Introduction 5 2.2.2. Active substance 5 2.2.3. Finished medicinal product 7 2.2.4

2013 European Medicines Agency - EPARs

18. Memantine LEK

Memantine LEK London, 21 February 2013 EMA/227468/2013 Committee for Medicinal Products for Human Use (CHMP) Assessment report Memantine LEK International non-proprietary name: Memantine Procedure No. EMEA/H/C/002630 Assessment Report as adopted by the CHMP with all information of a commercially confidential nature deleted 7 Westferry Circus ? Canary Wharf ? London E14 4HB ? United Kingdom An agency of the European Union Telephone +44 (0)20 7418 8400 Facsimile +44 (0)20 7418 8545 E-mail info (...) . Pharmacovigilance 17 3. Benefit-risk balance 17 4. Recommendation 18 Memantine LEK EMA/227468/2013 Page 2/18 List of abbreviations AEs adverse events Al or Alu Aluminium ASMF active substance master file AUC0-t Area under the plasma concentration curve from administration to last observed concentration at time t. AUC0- 8 Area under the plasma concentration curve extrapolated to infinite time BE Bioequivalence BMI body mass index Cmax Maximum plasma concentration CLcr creatinine clearance CHMP or CPMP Committee

2013 European Medicines Agency - EPARs

19. Balaxur (memantine hydrochloride / donepezil hydrochloride)

Balaxur (memantine hydrochloride / donepezil hydrochloride) 18 October 2012 EMA/817438/2012 Committee for Medicinal Products for Human Use (CHMP) Assessment report Balaxur International non-proprietary name: memantine hydrochloride / donepezil hydrochloride Procedure No. EMEA/H/C/002708 Note Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted. 7 Westferry Circus ? Canary Wharf ? London E14 4HB ? United Kingdom An agency of the European (...) Assessment report Page 2/63 IMP Investigational medicinal product IMS-IPD IMS-Prescribing Insights Database ip intraperitoneal IT Italy ITT Intent to treat LC/MS/MS Liquid chromatography with tandem mass spectrometric detection LOCF Last observation carried forward Log Kow octanol-water partition coefficient MADRS Montgomery and åsberg depression rating scale MCID Minimal clinically important difference MDS Minimum data set MEM/DPZ Memantine/ donepezil MMSE Mini mental state examination MoA Mechanism

2013 European Medicines Agency - EPARs

20. Acrescent (memantine hydrochloride / donepezil hydrochloride)

Acrescent (memantine hydrochloride / donepezil hydrochloride) 18 October 2012 EMA/111381/2013 Committee for Medicinal Products for Human Use (CHMP) Assessment report Acrescent International non-proprietary name: memantine hydrochloride / donepezil hydrochloride Procedure No. EMEA/H/C/002424 Note Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted. 7 Westferry Circus ? Canary Wharf ? London E14 4HB ? United Kingdom An agency of the European (...) Assessment report Page 2/63 IMP Investigational medicinal product IMS-IPD IMS-Prescribing Insights Database ip intraperitoneal IT Italy ITT Intent to treat LC/MS/MS Liquid chromatography with tandem mass spectrometric detection LOCF Last observation carried forward Log Kow octanol-water partition coefficient MADRS Montgomery and åsberg depression rating scale MCID Minimal clinically important difference MDS Minimum data set MEM/DPZ Memantine/ donepezil MMSE Mini mental state examination MoA Mechanism

2013 European Medicines Agency - EPARs